Metastatic Castration-Resistant Prostate Cancer Facts - Verywell Health Metastatic castration-resistant prostate cancer (mCRPC) is a complex and serious condition, but doctors and scientists are making progress every year While it is not yet curable, treatment options are available These include advanced hormone therapies, chemotherapy, immunotherapy, radiation, targeted therapies, and supportive care
Metastatic Castration-Resistant Prostate Cancer: Insights on Current . . . The therapeutic landscape of metastatic hormone sensitive and metastatic castration-resistant prostate cancer (mCRPC) is rapidly changing Loriot Y, Fizazi K, de Bono JS, Forer D, Hirmand M, Scher HI Enzalutamide in castration-resistant prostate cancer patients with visceral disease in the liver and or lung: outcomes from the randomized
Hormone Therapy for Prostate Cancer Fact Sheet - NCI Abiraterone is used in combination with prednisone to treat metastatic prostate cancer, both castration-sensitive and castration-resistant Ketoconazole is approved for indications other than prostate cancer but is sometimes used off-label as second-line treatment for castration-resistant prostate cancer, although such use is rare given the
Treatments for castration-resistant prostate cancer It can also be called hormone-refractory or hormone-resistant prostate cancer Non-metastatic castration-resistant prostate cancer has not spread to other parts of the body (based on bone scans and CT scans) Metastatic castration-resistant prostate cancer has spread to lymph nodes or other parts of the body, such as the bones
Metastatic Castration-Resistant Prostate Cancer (mCRPC) In Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC), cancer grows after hormone treatment Scans may show that it has not yet spread to other parts of the body In the advanced form of prostate cancer, it becomes metastatic It spreads beyond the prostate to other parts of the body With Metastatic Castration-Resistant Prostate
Metastatic Castration-Resistant Prostate Cancer: Advances in Treatment . . . The management of metastatic castrate-resistant prostate cancer (mCRPC) has evolved in the past decade due to substantial advances in understanding the genomic landscape and biology underpinning this form of prostate cancer The implementation of various therapeutic agents has improved overall survival but despite the promising advances in therapeutic options, mCRPC remains incurable The
Metastatic Prostate Cancer Treatments Docetaxel (Taxotere ®) is considered the standard of care in chemotherapy for prostate cancer that is resistant to hormone therapy It works by damaging the structure of prostate cancer cells Another chemotherapy drug for treating castration-resistant prostate cancer is cabazitaxel (Jevtana ®) It’s also used by people with metastatic